Ultrasound Guidelines for Uncomplicated Pregnancy
For an uncomplicated, low-risk pregnancy, one standard transabdominal anatomy scan between 18-20 weeks of gestation is the recommended minimum, with no routine third-trimester ultrasound indicated unless specific clinical concerns arise. 1, 2
Standard Ultrasound Schedule for Low-Risk Pregnancy
First Trimester (Optional but Common)
- Early dating scan can be performed to establish gestational age, confirm viability, determine number of fetuses, and assess chorionicity in multiple pregnancies 2, 3
- Nuchal translucency screening at 10-14 weeks (specifically 12-13 weeks optimal) serves as a screening tool for chromosomal abnormalities and can detect approximately 27% of structural anomalies 2, 3
- First trimester ultrasound improves detection of multiple pregnancies and provides more accurate gestational dating, which reduces unnecessary inductions for presumed post-term pregnancy 4
Second Trimester (Required)
- Anatomy scan at 18-20 weeks is the single most important ultrasound for all pregnant women, regardless of risk status 1, 2
- This scan evaluates fetal structural development, placental location, amniotic fluid volume, and screens for major congenital anomalies 1
- Routine early pregnancy ultrasound significantly improves detection of major fetal abnormalities before 24 weeks (3.46-fold increase in detection) 4
Third Trimester (Not Routinely Recommended)
- No routine third-trimester ultrasound is recommended for low-risk pregnancies, as multiple trials have not demonstrated improved antenatal, obstetric, or neonatal outcomes 1, 2, 5
- Five of six major guidelines (83%) explicitly recommend against routine third-trimester scanning in low-risk women 1
When Additional Scans Are Indicated
Soft Markers Found on Anatomy Scan
If isolated soft markers are detected on the 18-20 week scan with negative aneuploidy screening:
- Echogenic intracardiac focus: No further ultrasound follow-up needed—this is a normal variant 1, 2
- Choroid plexus cysts: No further ultrasound follow-up needed if isolated 1, 2
- Echogenic bowel: Third-trimester ultrasound for reassessment and growth evaluation 2
- Single umbilical artery: Third-trimester ultrasound for growth evaluation, with consideration of weekly surveillance starting at 36 weeks 2
- Urinary tract dilation A1 (low risk): Follow-up ultrasound at ≥32 weeks 1, 2
- Urinary tract dilation A2-3 (increased risk): Individualized follow-up schedule with planned postnatal evaluation 1, 2
- Shortened humerus or femur: Third-trimester ultrasound for reassessment and growth evaluation 2
Major Anomalies Detected
- Detailed ultrasound scan should be performed immediately or scheduled soon after detection of any major anomaly on routine screening 1
- Serial follow-up scans are indicated for growth monitoring, delivery planning, and postnatal management if pregnancy continues 1
- Fetal MRI may be indicated at ≥22 weeks for incomplete ultrasound information, particularly for CNS anomalies, thoracic masses, or complex malformations 1
Common Pitfalls to Avoid
Unnecessary Follow-Up Scans
- Do not perform repeat ultrasounds for isolated echogenic intracardiac focus or isolated choroid plexus cysts when aneuploidy screening is negative—these are normal variants requiring no further evaluation 1, 2
- Avoid routine third-trimester scanning in truly low-risk pregnancies, as this increases healthcare costs without improving outcomes 1, 5
Timing Considerations
- For maternal obesity (BMI ≥35): Delay anatomy scan to 20-22 weeks due to suboptimal visualization, with repeat follow-up in 2-4 weeks if initial scan is incomplete 2
- Fundal height measurements are unreliable in women with obesity or fibroids; consider ultrasound for growth assessment at 28-32 weeks in these patients 1, 2
Diagnostic Testing Decisions
- Do not recommend diagnostic testing (amniocentesis) solely for isolated soft markers when serum or cell-free DNA screening is negative 1
- For isolated thickened nuchal fold or absent/hypoplastic nasal bone with negative screening, counsel about options but do not mandate invasive testing 1